TG Therapeutics Statistics
Share Statistics
TG Therapeutics has 155.66M shares outstanding. The number of shares has increased by 0.81% in one year.
| Shares Outstanding | 155.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.54% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 140.52M |
| Failed to Deliver (FTD) Shares | 62 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 27.14M, so 17.43% of the outstanding shares have been sold short.
| Short Interest | 27.14M |
| Short % of Shares Out | 17.43% |
| Short % of Float | 19.32% |
| Short Ratio (days to cover) | 8.95 |
Valuation Ratios
The PE ratio is 191.33 and the forward PE ratio is 32.02. TG Therapeutics 's PEG ratio is 0.07.
| PE Ratio | 191.33 |
| Forward PE | 32.02 |
| PS Ratio | 10.38 |
| Forward PS | 6.2 |
| PB Ratio | 15.11 |
| P/FCF Ratio | -77.18 |
| PEG Ratio | 0.07 |
Enterprise Valuation
TG Therapeutics Inc. has an Enterprise Value (EV) of 2.44B.
| EV / Earnings | 192.74 |
| EV / Sales | 10.45 |
| EV / EBITDA | 93.58 |
| EV / EBIT | 118.38 |
| EV / FCF | -77.75 |
Financial Position
The company has a current ratio of 5.92, with a Debt / Equity ratio of 0.62.
| Current Ratio | 5.92 |
| Quick Ratio | 5.18 |
| Debt / Equity | 0.62 |
| Total Debt / Capitalization | 38.42 |
| Cash Flow / Debt | -0.31 |
| Interest Coverage | 1.64 |
Financial Efficiency
Return on equity (ROE) is 0.08% and return on capital (ROIC) is 7.38%.
| Return on Equity (ROE) | 0.08% |
| Return on Assets (ROA) | 0.04% |
| Return on Capital (ROIC) | 7.38% |
| Revenue Per Employee | 732.48K |
| Profits Per Employee | 39.72K |
| Employee Count | 319 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 0.35 |
Taxes
| Income Tax | 390.00K |
| Effective Tax Rate | 0.03 |
Stock Price Statistics
The stock price has increased by 96.11% in the last 52 weeks. The beta is 2.19, so TG Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.19 |
| 52-Week Price Change | 96.11% |
| 50-Day Moving Average | 31.15 |
| 200-Day Moving Average | 22.44 |
| Relative Strength Index (RSI) | 47.04 |
| Average Volume (20 Days) | 2.97M |
Income Statement
In the last 12 months, TG Therapeutics had revenue of 233.66M and earned 12.67M in profits. Earnings per share was 0.09.
| Revenue | 233.66M |
| Gross Profit | 219.53M |
| Operating Income | 20.63M |
| Net Income | 12.67M |
| EBITDA | 26.10M |
| EBIT | 20.63M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 92.93M in cash and 110.80M in debt, giving a net cash position of -17.86M.
| Cash & Cash Equivalents | 92.93M |
| Total Debt | 110.80M |
| Net Cash | -17.86M |
| Retained Earnings | -1.51B |
| Total Assets | 586.01M |
| Working Capital | 448.95M |
Cash Flow
In the last 12 months, operating cash flow was -31.41M and capital expenditures 0, giving a free cash flow of -31.41M.
| Operating Cash Flow | -31.41M |
| Capital Expenditures | 0 |
| Free Cash Flow | -31.41M |
| FCF Per Share | -0.22 |
Margins
Gross margin is 93.95%, with operating and profit margins of 8.83% and 5.42%.
| Gross Margin | 93.95% |
| Operating Margin | 8.83% |
| Pretax Margin | 5.59% |
| Profit Margin | 5.42% |
| EBITDA Margin | 11.17% |
| EBIT Margin | 8.83% |
| FCF Margin | -13.44% |
Dividends & Yields
TGTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.3% |
| FCF Yield | -0.68% |
Analyst Forecast
The average price target for TGTX is $41.5, which is 39.6% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.5 |
| Price Target Difference | 39.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Apr 30, 2012. It was a backward split with a ratio of 4:225.
| Last Split Date | Apr 30, 2012 |
| Split Type | backward |
| Split Ratio | 4:225 |
Scores
| Altman Z-Score | 4.76 |
| Piotroski F-Score | 2 |